Sudarshan Pharma reported a 57% YoY increase in standalone net profit to ₹21.98 crore for FY26.
Revenue from operations grew 33% YoY to ₹667.50 crore for the full financial year ended March 2026.
The board approved audited standalone and consolidated financial results for Q4 and FY26 per SEBI Regulation 33.
Company received ₹4.68 crore from a Dubai court award and plans to raise ₹1,500 crore via FCCBs.